Literature DB >> 27666131

Postoperative seizure control in patients with tumor-associated epilepsy.

Andrew Neal1,2, Andrew Morokoff3,4, Terence John O'Brien1,2, Patrick Kwan1,2.   

Abstract

OBJECTIVE: The patterns of postoperative seizure control and response to antiepileptic drugs (AEDs) in tumor-associated epilepsy (TAE) are poorly understood. We aim to document these characteristics in patients with supratentorial gliomas.
METHODS: This was a retrospective analysis of 186 patients with supratentorial gliomas. Seizure patterns were classified into four groups: A, no postoperative seizure; B, early postoperative seizure control within 6 months; C, fluctuating seizure control; and D, never seizure-free. Rates and duration of seizure freedom, subsequent seizure relapse, and response to AED were analyzed.
RESULTS: Among patients included, 49 (26.3%) had grade II, 28 (15.1%) had grade III, and 109 (58.6%) had grade IV glioma. Outcome pattern A was observed in 95 (51.1%), B in 22 (11.8%), C in 45 (24.2%), and D in 24 (12.9%). One hundred nineteen patients had at least one seizure and were classified as having TAE. Compared to pattern A, pattern B was predicted by histologic progression; pattern C by tumor grade, preoperative seizure, and histologic progression, and pattern D by preoperative seizure and gross total resection. Among patients with TAE, 57.5% of grade II, 68.2% of grade III, and 26.3% of grade IV experienced a period of 12-month seizure freedom. After first 12-month seizure remission, 39.1%, 60.0%, and 13.3% of grade II, III, and IV gliomas, respectively, experienced subsequent seizure; 22.6% of those with TAE reached terminal seizure freedom of at least 12 months on their first postoperative AED regimen, 6.5% on their second regimen, and 5.4% on subsequent regimens. SIGNIFICANCE: Distinct patterns of postoperative seizure control exist in gliomas; they have specific risk factor profiles, and we hypothesize these correspond to unique pathogenic mechanisms. Twelve-month seizure freedom with subsequent relapse is frequent in grade II-III gliomas. Response to AEDs is markedly poorer than with non-TAE, highlighting the complex epileptogenicity of gliomas. Wiley Periodicals, Inc.
© 2016 International League Against Epilepsy.

Entities:  

Keywords:  Epilepsy; Glioma; Seizure; Tumor

Mesh:

Substances:

Year:  2016        PMID: 27666131     DOI: 10.1111/epi.13562

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

Review 1.  Neuro-Oncology and Radiogenomics: Time to Integrate?

Authors:  A Lasocki; M A Rosenthal; S J Roberts-Thomson; A Neal; K J Drummond
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-10       Impact factor: 3.825

2.  Risk factors and control of seizures in 778 Chinese patients undergoing initial resection of supratentorial meningiomas.

Authors:  Xiangrong Li; Chengjun Wang; Zhiqin Lin; Meng Zhao; Xiaohui Ren; Xiaohui Zhang; Zhongli Jiang
Journal:  Neurosurg Rev       Date:  2019-02-15       Impact factor: 3.042

3.  Postoperative epilepsy and survival in glioma patients: a nationwide population-based cohort study from 2009 to 2018.

Authors:  Mirketa Marku; Birthe Krogh Rasmussen; Federica Belmonte; Elisabeth Anne Wreford Andersen; Christoffer Johansen; Pernille Envold Bidstrup
Journal:  J Neurooncol       Date:  2022-01-28       Impact factor: 4.130

4.  Tumor type, epilepsy burden, and seizure documentation: experiences at a single center neuro-oncology clinic.

Authors:  Omar Bushara; Alex Guzner; Elizabeth Bachman; Roger Stupp; Rimas V Lukas; Jessica W Templer
Journal:  Neurooncol Pract       Date:  2021-06-11

5.  Pre- and Post-surgical Poor Seizure Control as Hallmark of Malignant Progression in Patients With Glioma?

Authors:  Giada Pauletto; Annacarmen Nilo; Christian Lettieri; Lorenzo Verriello; Barbara Tomasino; Gian Luigi Gigli; Miran Skrap; Tamara Ius
Journal:  Front Neurol       Date:  2022-05-16       Impact factor: 4.086

6.  Postoperative seizure outcome and timing interval to start antiepileptic drug withdrawal: A retrospective observational study of non-neoplastic drug resistant epilepsy.

Authors:  Le Zhang; Xin-Yue Jiang; Dong Zhou; Heng Zhang; Shi-Min Bao; Jin-Mei Li
Journal:  Sci Rep       Date:  2018-09-13       Impact factor: 4.379

7.  Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging.

Authors:  Andrew Neal; Bradford A Moffat; Joel M Stein; Ravi Prakash Reddy Nanga; Patricia Desmond; Russell T Shinohara; Hari Hariharan; Rebecca Glarin; Katharine Drummond; Andrew Morokoff; Patrick Kwan; Ravinder Reddy; Terence J O'Brien; Kathryn A Davis
Journal:  Neuroimage Clin       Date:  2019-01-29       Impact factor: 4.881

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.